Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

Clinical Characteristics, Risk Factors and Resistance Mechanisms for Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

This study aims to determine the clinical characteristics, risk factors, and resistance mechanisms of patients with carbapenem-resistant P. mirabilis bacteremia.Patients with P. mirabilis growth in blood culture samples sent to bacteriology laboratory between 2018 and 2021 were retrospectively analyzed. Patients meeting the inclusion criteria were divided into carbapenem-resistant and carbapenem- susceptible groups. The investigators recorded demographic data, clinical features, and laboratory findings. Resistance genes were investigated in carbapenem-resistant isolates using PCR.

Study Overview

• Status: Completed
• Conditions: Bacteremia; Carbapenem Resistant Bacterial Infection; Proteus Mirabilis Infection
• Intervention / Treatment: Other: Non-Interventional Research

Detailed Description

Patients with P. mirabilis growth in blood culture who met the study criteria were divided into two groups as carbapenem susceptible and resistant according to carbapenem antibiogram results. Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group and patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group.

Demographic characteristics of the patients, concomitant chronic diseases, Charlson comorbidity index (CCI), hospital and intensive care unit (ICU) hospitalization and number of days in the last year, history and type of invasive intervention in the last three months (surgical-invasive), history of antibiotic use in the last three months and types of antibiotics used (Penicillin, cephalosporin, quinolone, carbapenem, tigecycline, colistin, aminoglycoside), hospitalization unit, total length of hospitalization, sample collection unit, growth result and antibiogram, clinical and laboratory data of the day of growth, sepsis and septic shock evaluated according to systemic inflammatory response syndrome (SIRS) criteria, 30-day mortality and patient outcome information were recorded.

Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction (PCR) in accessible samples of patients with carbapenem-resistant P. mirabilis growth in blood cultures.

• Study Type: Observational
• Enrollment (Actual): 67

Contacts and Locations

Study Locations

• Turkey
  • İzmir, Turkey, 35400
    • Dokuz Eylul University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

. Inpatients aged 18 years and older with P. mirabilis growth in blood cultures were included in the study, while samples taken in emergency departments, outpatient clinics, day treatment units and recurrent growths of the same patient were excluded.

Description

Inclusion Criteria:

• Inpatients aged 18 years and older
• P. mirabilis growth in blood cultures

Exclusion Criteria:

• Samples taken in emergency departments, outpatient clinics, day treatment units
• Recurrent growths of the same patient

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Case (Patients with carbapenem-resistant P. mirabilis); Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group	Other: Non-Interventional Research; Non-Interventional Research
Control (Patients with carbapenem- susceptible P. mirabilis); Patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group	Other: Non-Interventional Research; Non-Interventional Research

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Carbapenem Use	number of patients using carbapenem before P. mirabilis growth in blood cultures	1 year
Intensive Care Units	number of patients admission in ıntensive care units before P. mirabilis growth in blood cultures	1 year
Mortality	number of patients who died	30 days
Length of hospital stay	Length of hospital stay days	1 year
Presence of chronic disease	number of patients with chronic disease	1 year

Collaborators and Investigators

• Sponsor: Dokuz Eylul University
• Investigators: Principal Investigator: Çağlar IRMAK, Dokuz Eylul University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2018
• Primary Completion (Actual): December 31, 2021
• Study Completion (Actual): January 1, 2023

Study Registration Dates

• First Submitted: July 31, 2024
• First Submitted That Met QC Criteria: August 3, 2024
• First Posted (Actual): August 7, 2024

Study Record Updates

• Last Update Posted (Actual): August 7, 2024
• Last Update Submitted That Met QC Criteria: August 3, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Keywords: PCR; bacteremia; carbapenem resistance; Proteus mirabilis; resistance mechanisms
• Additional Relevant MeSH Terms: Pathologic Processes; Systemic Inflammatory Response Syndrome; Inflammation; Disease Attributes; Gram-Negative Bacterial Infections; Bacterial Infections and Mycoses; Enterobacteriaceae Infections; Sepsis; Infections; Communicable Diseases; Bacteremia; Bacterial Infections; Proteus Infections
• Other Study ID Numbers: DEU-INF-IRMAK-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No